PFM Health Sciences’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-1,465,483
Closed -$35.7M 94
2023
Q1
$35.7M Buy
1,465,483
+547,926
+60% +$12M 1.57% 31
2022
Q4
$19.6M Buy
917,557
+661,273
+258% +$14.1M 0.7% 53
2022
Q3
$4.6M Sell
256,284
-649,732
-72% -$8.53M 0.17% 76
2022
Q2
$8.72M Sell
906,016
-99,200
-10% -$1.25M 0.33% 62
2022
Q1
$16.9M Hold
1,005,216
0.63% 49
2021
Q4
$16.8M Sell
1,005,216
-132,896
-12% -$2.18M 0.57% 51
2021
Q3
$18.5M Buy
+1,138,112
New +$12.4M 0.54% 56
2017
Q1
Sell
-113,382
Closed -$548K 125
2016
Q4
$548K Buy
+113,382
New +$3.37M 0.02% 93

Other funds holding ISEE

PFM Health Sciences's ISEE Position: Q2 2023 in Review

PFM Health Sciences sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q2 2023, closing a stake of 1,465,483 shares — an estimated $35.7M sold.

PFM Health Sciences first reported a position in ISEE in Q4 2016 and held it in 8 quarters. The position peaked at $35.7M in Q1 2023. 256 funds tracked by Wall St. Rank hold ISEE as of Q2 2023.

  • PFM Health Sciences reported no remaining IVERIC bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • PFM Health Sciences sold 1,465,483 IVERIC bio, Inc. Common Stock shares in Q2 2023, an estimated $35.7M.
  • PFM Health Sciences first reported a position in IVERIC bio, Inc. Common Stock in Q4 2016 and held it in 8 quarters.
  • PFM Health Sciences's IVERIC bio, Inc. Common Stock position peaked at $35.7M in Q1 2023.
  • 256 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q2 2023.

Based on PFM Health Sciences's 13F filing for Q2 2023, filed 14 Aug 2023.